Aarti Industries Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/8frlzb894c5k4qfv9gwpj83n.pdf

Key Takeaways


Volume Strategy & Operating Performance

Suyog Kotecha: "I think improving utilization levels of all of our existing assets has been a deliberate strategy. And I think we have pushed volumes sometimes even at the expense of a slight compromise on the margins."

Zone IV & Capex Execution

Suyog Kotecha: "Our target as a management team still remains on how to do catch up even with the 3 to 4 months of delay. But at the same time, we are transparent in communicating in terms of how are we progressing against our initiatives, right?"

Balance Sheet & Working Capital


MMA Market Dynamics

Suyog Kotecha: "I do not think there is any conclusive trend at this point in time, which we can draw. And I do not think we will reach a stability until the situation in the Middle East is kind of directionally at least settled."

Long-Term Contracts & Partnerships

Suyog Kotecha: "I think it is one thing to get a long-term contract. But if the same major comes back to you with a repeat long-term contract, that also gives you a significant validation of the value proposition that you are putting up in this partnership, and that was very heartening to see."

China Dynamics & Margin Recovery

Suyog Kotecha: "The narrative that we are hearing what we are seeing, I think if that persists and that becomes much more broad-based, we might see a recovery in the margin. But I think we wait to see a firmer trend to make a conclusive commentary on the segment."

Guidance & Commitments

CommitmentSpecificsTimeline
Zone IV commissioningCalcium chloride and MPP under trials; remaining 5 chemistry blocks to followCalcium chloride and MPP in Q1 FY27; all blocks throughout FY27
Zone IV initial revenueRevenue contribution to beginQ2 FY27
Zone IV revenue potentialHit previously communicated rangeOver course of 2 years
Incremental EBITDA from Zone IV/MPP/UPL JV₹300–450 crore, delayed by 6–7 months from original timelinePotentially beyond FY28
FY27 capex₹700–800 croreFY27
Net debtDecline from current levelsFY27
Cash flow vs. capexCash flow expected to exceed planned capexFY27
Augene JV commissioningCommission and ramp to full utilizationJune/July 2026; full utilization within FY27
Recycling JV commissioningCommission within calendar year; meaningful contribution may take timeCY26
Tax rate9% to 15% rangeGoing forward
China anti-involution benefitBenefits to PNCB-related products in NCB chainFrom Q1 FY27 onwards
Raw material price pass-through (agro)Full pass-through, conditional on raw material stabilityNext 3–6 months

Key Metrics

MetricQ4 FY26
Revenue₹2,422 cr, +9% YoY
EBITDA₹342 cr, +29% YoY
Profit after tax₹137 cr, +43% YoY
Full-year FY26 revenue₹9,018 cr, +12% YoY
Full-year FY26 EBITDA₹1,172 cr, +15% YoY
Full-year FY26 PAT₹419 cr, +27% YoY
FY26 capex₹1,125 cr, in line with guidance
FY27 capex guidance₹700–800 cr
Net debt₹4,300 cr, net debt-to-EBITDA at 3.6x
Energy application revenue share~40% of total revenue
Energy application volumes-4% QoQ, impacted by lower exports to Middle East
Middle East revenue exposure~9–10% of total revenue on yearly average, dominantly in energy
Exports share of revenue57% of total revenue in Q4
FX revaluation loss on long-term foreign currency loan₹39 cr, on $87 mn unhedged exposure
New multiyear supply agreement$150 mn with global agrochemical innovator, extending through March 31, 2030
Zone IV project delay3–4 months due to contract labour constraints